纳武利尤单抗联合卡博替尼对比舒尼替尼一线治疗晚期肾细胞癌(CheckMate 9ER):开放标签、随机、3期试验的长期随访结果
CheckMate 9ER是一项在18个国家125家医院开展的开放标签、随机3期试验,纳入既往未治疗的晚期或转移性透明细胞肾细胞癌患者,1:1随机接受纳武利尤单抗联合卡博替尼或舒尼替尼治疗。中位随访32.9个月时,联合组中位总生存期37.7个月 vs 舒尼替尼组34.3个月(HR 0.70,p=0.0043),中位无进展生存期16.6个月 vs 8.3个月(HR 0.56,p<0.0001)。
要点
- 中位随访32.9个月,联合组中位总生存期37.7个月 vs 舒尼替尼组34.3个月(HR 0.70,95%CI 0.55-0.90,p=0.0043)。
- 联合组中位无进展生存期16.6个月 vs 舒尼替尼组8.3个月(HR 0.56,95%CI 0.46-0.68,p<0.0001)。
- 3-4级治疗相关不良事件联合组208/320例(65%) vs 舒尼替尼组172/320例(54%)。
核心结论
- 延长随访并按方案进行预设最终总生存分析,纳武利尤单抗联合卡博替尼较舒尼替尼显示更优疗效,进一步支持该联合方案用于晚期肾细胞癌一线治疗。
研究设计与样本
- 开放标签、随机、3期试验,在18个国家125家医院和癌症中心开展。
- 纳入年龄18岁及以上、既往未治疗的晚期或转移性透明细胞肾细胞癌患者,Karnofsky体能状态评分70%或以上,研究者按RECIST 1.1评估有可测量病灶,任何IMDC预后风险类别,并有可用于PD-L1检测的肿瘤组织。
- 患者1:1随机接受纳武利尤单抗240 mg静脉注射每2周联合卡博替尼40 mg口服每日一次,或舒尼替尼50 mg口服每日一次(每6周为一周期,用4周)。
- 随机按IMDC风险状态、肿瘤PD-L1表达和地理区域分层,采用区组大小为4的置换区组法,通过交互式应答系统进行。
- 主要终点为盲法独立中心评审的无进展生存期;总生存期为次要终点,本文报告按方案预设的最终分析。
主要发现
- 数据截止2021年6月24日,中位随访32.9个月(IQR 30.4-35.9),联合组中位总生存期37.7个月(95%CI 35.5-不可估计) vs 舒尼替尼组34.3个月(95%CI 29.0-不可估计),HR 0.70(95%CI 0.55-0.90),p=0.0043。
- 更新中位无进展生存期联合组16.6个月(95%CI 12.8-19.8) vs 舒尼替尼组8.3个月(95%CI 7.0-9.7),HR 0.56(95%CI 0.46-0.68),p<0.0001。
- 3-4级治疗相关不良事件:联合组208/320例(65%) vs 舒尼替尼组172/320例(54%)。
- 最常见的3-4级治疗相关不良事件:高血压联合组40/320例(13%) vs 舒尼替尼组39/320例(12%);手足红斑感觉异常综合征25/320例(8%) vs 26/320例(8%);腹泻22/320例(7%) vs 15/320例(5%)。
- 3-4级治疗相关严重不良事件:联合组70/320例(22%) vs 舒尼替尼组31/320例(10%);舒尼替尼组另发生1例治疗相关死亡(猝死)。
临床怎么用
- 作者认为,延长随访和预设最终总生存分析显示纳武利尤单抗联合卡博替尼较舒尼替尼疗效更优,进一步支持该联合方案用于晚期肾细胞癌一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously untreated advanced renal cell carcinoma (median follow-up of 18·1 months). Here, we report extended follow-up of overall survival and updated efficacy and safety. METHODS: This open-label, randomised, phase 3 trial was done in 125 hospitals and cancer centres across 18 countries. We included patients aged 18 years or older with previously untreated advanced or metastatic clear-cell renal cell carcinoma, a Karnofsky performance status of 70% or higher, measurable disease according to Response Evaluation Criteria in Solid Tumors version 1.1 assessed by the investigator, any International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic risk category, and available tumour tissue for PD-L1 testing. Patients were randomly assigned (1:1) to nivolumab (240 mg) intravenously every 2 weeks plus cabozantinib (40 mg) orally once daily or sunitinib (50 mg orally) once daily (4 weeks per 6-week cycle). Randomisation, stratified by IMDC risk status, tumour PD-L1 expression, and geographical region, was done by permuted block within each stratum using a block size of four, via an interactive response system. The primary endpoint was progression-free survival by blinded independent central review. Overall survival was a secondary endpoint (reported here as the preplanned final analysis according to the protocol). Efficacy was assessed in all randomly assigned patients; safety was assessed in all patients who received at least one dose of any study drug. This ongoing study, closed to recruitment, is registered with ClinicalTrials.gov, NCT03141177. FINDINGS: Between Sept 11, 2017, and May 14, 2019, 323 patients were randomly assigned to the nivolumab plus cabozantinib group and 328 to the sunitinib group. With an extended follow-up (data cutoff of June 24, 2021; median 32·9 months [IQR 30·4-35·9]), median overall survival was 37·7 months (95% CI 35·5-not estimable) in the nivolumab plus cabozantinib group and 34·3 months (29·0-not estimable) in the sunitinib group (hazard ratio [HR] 0·70 [95% CI 0·55-0·90], p=0·0043) and updated median progression-free survival was 16·6 months (12·8-19·8) versus 8·3 months (7·0-9·7; HR 0·56 [95% CI 0·46-0·68], p<0·0001). Grade 3-4 treatment-related adverse events occurred in 208 (65%) of 320 patients with nivolumab plus cabozantinib versus 172 (54%) of 320 with sunitinib. The most common grade 3-4 treatment-related adverse events were hypertension (40 [13%] of 320 patients in the nivolumab plus cabozantinib group vs 39 [12%] of 320 in the sunitinib group), palmar-plantar erythrodysaesthesia (25 [8%] vs 26 [8%]), and diarrhoea (22 [7%] vs 15 [5%]). Grade 3-4 treatment-related serious adverse events occurred in 70 (22%) of 320 patients in the nivolumab plus cabozantinib group and 31 (10%) of 320 in the cabozantinib group. One additional treatment-related death occurred with sunitinib (sudden death). INTERPRETATION: With extended follow-up and preplanned final overall survival analysis per protocol, nivolumab plus cabozantinib demonstrated improved efficacy versus sunitinib, further supporting the combination in the first-line treatment of advanced renal cell carcinoma. FUNDING: Bristol Myers Squibb and Ono Pharmaceutical.
引用
- Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022. PMID: 35688173. doi:10.1016/S1470-2045(22)00290-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。